GlassScriptPhysician profile
Karan Sheth
NPI 1790404960
$2,933.18
in general payments reported to CMS, 2019-2025
29 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $336 · 2024: $1,570 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $584.12 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $458.97 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $456.10 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $247.29 | 2023-2025 | |
| Amgen INC. | $173.26 | 2024-2025 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $96.23 | 2023-2024 | Verquvo, Belsomra |
| Exact Sciences Corporation | $94.92 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $90.10 | 2024-2025 | |
| Radius Health, INC. | $64.81 | 2024-2025 | Tymlos |
| Lilly USA, LLC | $60.34 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $57.48 | 2024-2025 | Gvoke Hypopen |
| Pfizer INC. | $53.16 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.28 | 2023-2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $42.47 | 2023-2024 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $42.18 | 2024-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $40.11 | 2024 | Senza |
| Esperion Therapeutics, INC. | $39.61 | 2023-2024 | Nexletol |
| Astellas Pharma US INC | $34.26 | 2024 | Veozah |
| Ardelyx, INC. | $31.82 | 2024 | Ibsrela |
| Dexcom, INC. | $29.53 | 2023-2025 | Dexcom G6 Transmitter |
| Forte Bio-Pharma LLC | $25.84 | 2023 | Prolate, Nalocet |
| Abbott Laboratories | $25.78 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $25.60 | 2024 | Gemtesa |
| Viatris Specialty LLC | $23.84 | 2025 | Yupelri |
| Corcept Therapeutics | $23.64 | 2025 | Korlym |
| Daiichi Sankyo INC. | $23.50 | 2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.94 | 2024 | Jardiance |
| Irhythm Technologies, INC. | $14.61 | 2024 | Zio Xt Patch, Zio Monitor |
| Phathom Pharmaceuticals, INC. | $11.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.